Completed PHASE2 INTERVENTIONAL 3-arm NCT00610428

Staccato Prochlorperazine in Migraine (in Clinic)

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of StaccatoTM Prochlorperazine for Inhalation in Patients With Migraine Headache

Sponsor: Alexza Pharmaceuticals, Inc.

Conditions Migraine Headache, With or Without Aura

Interventions Staccato Placebo Staccato Prochlorperazine 10 mg Staccato Prochlorperazine 5 mg

Updated 10 times since 2017 Last updated: Jun 17, 2017 Started: Mar 31, 2005 Primary completion: Oct 31, 2005 Completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Migraine Headache, With or Without Aura and is currently completed. Alexza Pharmaceuticals, Inc. leads this study, which shows 10 recorded versions since 2005 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE2
Sep 2024 — Feb 2026 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2018 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Feb 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alexza Pharmaceuticals, Inc.

Data source: Nova Pneuma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mount Vernon, United States